Ascendis Pharma director awarded 9,160-share warrant

Q: When do the new ASND warrants vest?

The new warrant vests 25% on April 14, 2027, and thereafter in 36 equal monthly installments.

The new warrant is scheduled to vest in stages beginning April 14, 2027, followed by 36 equal monthly installments.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Jean Jacques Bienaime, a director of Ascendis Pharma A/S (ASND), agreed to the cancellation of 9,160 warrants granted June 10, 2025, and was awarded a new warrant covering 9,160 underlying Ordinary Shares on April 14, 2026, as part of his board appointment. The cancelled warrant has an exercise price of 172.35 and expires June 10, 2035; it vests 25% on June 10, 2026, followed by 36 equal monthly installments. The new warrant has an exercise price of 249.84 and expires April 14, 2036. It vests 25% on April 14, 2027, followed by 36 equal monthly installments.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BIENAIME JEAN JACQUES

Role Director

Type	Security	Shares	Price	Value
Disposition	Warrants ^{F2, F1}	9,160	--	--
Grant/Award	Warrants ^{F2, F3}	9,160	--	--

Holdings After Transaction: Warrants — 9,160 contracts (Direct)

Footnotes (3)

F1. The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
F2. The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.
F3. The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.

Key Figures

Cancelled warrants: 9,160 warrants Cancelled-warrant exercise price: 172.35 per underlying Ordinary Share Cancelled-warrant expiration: June 10, 2035 +4 more

7 metrics

Cancelled warrants 9,160 warrants Cancellation agreed to April 14, 2026

Cancelled-warrant exercise price 172.35 per underlying Ordinary Share Warrant granted June 10, 2025

Cancelled-warrant expiration June 10, 2035 Warrant transaction dated April 14, 2026

New warrant award 9,160 warrants Awarded April 14, 2026

New-warrant exercise price 249.84 per underlying Ordinary Share Awarded as part of board appointment

New-warrant expiration April 14, 2036 Warrant awarded April 14, 2026

New-warrant vesting 25%, then 36 equal monthly installments Vesting begins April 14, 2027

Key Terms

warrants, exercise price, equal monthly installments

3 terms

warrants financial

"cancellation of 9,160 warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"has an exercise price of 172.35"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equal monthly installments financial

"followed by 36 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many warrants did ASND director Jean Jacques Bienaime cancel and receive?

On April 14, 2026, Jean Jacques Bienaime agreed to cancellation of 9,160 warrants granted June 10, 2025, and was awarded a new warrant covering 9,160 underlying Ordinary Shares as part of his board appointment.

When do the new ASND warrants vest?

The new warrant vests 25% on April 14, 2027, and thereafter in 36 equal monthly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/28/2026 - 04:08 PM Accepted by SEC EDGAR 09/28/2026 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last)

(First)

(Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP

2900

(City)

(State)

(Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants	$172.35	04/14/2026		D			9,160	⁽¹⁾	06/10/2035	Ordinary Shares	9,160	⁽²⁾	0	D
Warrants	$249.84	04/14/2026		A		9,160		⁽³⁾	04/14/2036	Ordinary Shares	9,160	⁽²⁾	9,160	D

Explanation of Responses:

1. The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.

2. The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.

3. The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.

	/s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR